PTGX Q4 2025 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-95.6% YoY

Gross Profit

$7M94.9% margin

Operating Income

-$50M-677.1% margin

Net Income

-$44M-596.8% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+57.8%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$36M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$670M

Total Liabilities

$55M

Stockholders' Equity

$615M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$171M	-95.6%
Gross Profit	$7M	$171M	-95.9%
Operating Income	-$50M	$127M	-139.7%
Net Income	-$44M	$132M	-133.7%